Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Biohaven Ltd.

Healthcare US BHVN

10.81USD
0.68(6.71%)

Last update at 2026-06-03T20:21:00Z

Day Range

9.9010.83
LowHigh

52 Week Range

7.4824.06
LowHigh

Fundamentals

  • Previous Close 10.13
  • Market Cap1532.79M
  • Volume3112200
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-698.44512M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-6.86

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -737.38000M -845.68700M -409.55100M -569.84100M -212.43000M
Minority interest - - - - -1.81000M
Net income -738.82200M -846.42200M -408.16800M -570.27900M -213.79600M
Selling general administrative 106.17M 89.24M 56.90M 130.86M 37.41M
Selling and marketing expenses - - 5.87M - -
Gross profit -4.14000M -3.92300M -3.36900M -1.38600M 370.85M
Reconciled depreciation 9.92M 7.86M 6.91M 1.39M 1.39M
Ebit -737.38000M -885.11100M -436.05100M -464.18500M -218.90000M
Ebitda -727.45800M -877.25600M -429.13900M -462.79900M -217.50700M
Depreciation and amortization 9.92M 7.86M 6.91M 1.39M 1.39M
Non operating income net other - - - - -65.43500M
Operating income -745.37800M -885.11100M -436.05100M -567.93200M -218.90000M
Other operating expenses 745.38M 885.11M 436.05M 567.93M 218.90M
Interest expense - - - 1.39M 41.55M
Tax provision 1.44M 0.73M -1.38300M 0.44M 1.37M
Interest income - - - - -
Net interest income - - - - -
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 1.44M 0.73M -1.38300M 0.44M 1.37M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 462.51M
Total operating expenses 741.24M 885.11M 436.05M 567.93M 218.90M
Cost of revenue 4.14M 3.92M 3.37M 1.39M 91.66M
Total other income expense net 8.00M 39.42M 26.50M -1.90900M 6.47M
Discontinued operations - - - - -
Net income from continuing ops -738.82200M -846.42200M -408.16800M -570.27900M -848.39600M
Net income applicable to common shares - - - -570.27900M -846.58600M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 451.45M 615.11M 513.21M 661.78M 142.06M
Intangible assets 18.40M 18.40M 18.40M 18.40M 18.40M
Earning assets - - - - -
Other current assets 49.19M 49.88M 47.38M 19.33M 2.12M
Total liab 399.38M 191.67M 85.24M 123.01M 47.37M
Total stockholder equity 52.07M 423.44M 427.98M 538.77M 34.69M
Deferred long term liab - - - - 13.11M
Other current liab 104.29M 132.40M 36.54M 79.32M 37.16M
Common stock 1934.28M 1656.70M 887.53M 615.74M 1676.79M
Capital stock 1934.28M 1656.70M 887.53M 615.74M -
Retained earnings -2084.53600M -1345.71400M -499.29200M -91.12400M -2585.75500M
Other liab - - - 2.41M 2.64M
Good will 1.39M 1.39M 1.39M 1.39M 1.39M
Other assets - - 0.00000M 2.58M 3.22M
Cash 229.96M 99.13M 248.40M 204.88M 76.06M
Cash and equivalents - - - - -
Total current liabilities 115.93M 154.23M 55.42M 90.02M 41.94M
Current deferred revenue - - - - -
Net debt 48.90M -62.55000M -217.52500M -174.29600M 550.66M
Short term debt - 3.80M 3.31M - 62.50M
Short long term debt - - - - -
Short long term debt total 278.86M 36.58M 30.88M 30.58M 626.72M
Other stockholder equity 193.98M 112.37M 39.80M 13.87M 169.66M
Property plant equipment - - - 52.14M 14.69M
Total current assets 368.33M 538.47M 442.45M 586.97M 94.82M
Long term investments - - - 0.00000M 6.00M
Net tangible assets - - - 518.68M -735.81800M
Short term investments 89.18M 386.86M 133.42M 260.46M 192.65M
Net receivables - 2.60M 13.65M 46.14M 9.91M
Long term debt 238.90M - - - 626.72M
Inventory - - -0.39600M 56.16M 6.73M
Accounts payable 11.64M 18.03M 15.58M 10.70M 4.78M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -3.62900M
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.35M 0.08M -0.06500M 0.28M -0.07300M
Additional paid in capital - - - - -
Common stock total equity - - - - 1676.79M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -2585.75500M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 47.36M 3.13M 2.40M 2.58M 3.22M
Deferred long term asset charges - - - - -
Non current assets total 83.12M 76.64M 70.77M 74.81M 47.24M
Capital lease obligations 45.71M 36.58M 30.88M 30.58M -
Long term debt total - - - - 626.72M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 303.12M -244.97400M 129.83M -304.79000M 28.27M
Change to liabilities - - - 5.93M 117.20M
Total cashflows from investing activities 300.56M -244.97400M 129.83M -304.79000M 26.55M
Net borrowings 250.00M 0.00000M 0.00000M - 420.44M
Total cash from financing activities 439.12M 677.77M 211.91M 767.60M 138.45M
Change to operating activities - - - -34.53200M 0.64M
Net income -738.82200M -846.42200M -408.16800M -570.27900M -213.79600M
Change in cash 130.24M -149.57800M 9.52M 165.55M -6.44900M
Begin period cash flow 102.54M 252.12M 242.60M 77.06M 83.51M
End period cash flow 232.78M 102.54M 252.12M 242.60M 77.06M
Total cash from operating activities -609.43800M -582.45300M -331.72500M -297.68900M -145.84000M
Issuance of capital stock 189.18M 666.16M 243.22M 283.80M -
Depreciation 9.92M 7.86M 6.91M 1.39M 1.39M
Other cashflows from investing activities -1.84900M 0.39M - - -
Dividends paid - - - - -
Change to inventory - - - - -24.10200M
Change to account receivables - - - - -188.15800M
Sale purchase of stock 1.83M 11.50M - - 345.63M
Other cashflows from financing activities -0.19400M 2.26M -31.31700M 483.79M 138.45M
Change to netincome - - - 299.81M 128.66M
Capital expenditures 0.71M 4.05M 3.05M 41.07M 0.94M
Change receivables - - - - -188.15800M
Cash flows other operating - - - - -41.24300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 40.30M
Change in working capital 1.36M 16.81M 24.61M -28.60400M 1.66M
Stock based compensation 112.36M 71.96M 28.79M 193.56M 65.64M
Other non cash items 5.74M 167.34M 16.13M 106.25M 4.52M
Free cash flow -610.15300M -586.50200M -334.77300M -338.76300M -146.77800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
BHVN
Biohaven Ltd.		 0.68 6.71% 10.81 - - - 31.26 -2.1877
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Biohaven Ltd.

215 Church Street, New Haven, CT, United States, 06510

Key Executives

Name Title Year Born
Dr. Vladimir Coric M.D. Chairman & CEO 1971
Mr. Matthew Buten Chief Financial Officer 1961
Mr. George C. Clark VP & Chief Accounting Officer 1984
Dr. Bruce D. Car DACVP, Ph.D. Chief Scientific Officer 1961
Ms. Jennifer Porcelli VP of Investor Relations NA
Mr. Warren Volles Gen. Counsel & Chief Legal Officer NA
Mr. Clifford Bechtold M.S. Chief Compliance Officer NA
Ms. Kimberly Gentile Sr. VP of Clinical Operations 1966
Mr. John Tilton Chief Commercial Officer of Rare Diseases 1968
Mr. Chris Barrett Sr. VP of Commercial Strategy, Common Disease NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions